Drug safety tested in people with kidney problems
NCT ID NCT07032272
Summary
This early-stage study aimed to understand how a new drug called remibrutinib is processed by the body in people with severe kidney impairment. It compared 16 participants—half with poor kidney function and half with healthy kidneys—to see if the drug behaves differently. The goal was to gather data to help doctors determine safe and effective doses for future patients with kidney issues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Pharmacology of Miami LLC
Miami, Florida, 33014-3616, United States
-
Genesis Clinical Research
Tampa, Florida, 33614, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
Panax Clinical Research
Miami Lakes, Florida, 33014, United States
Conditions
Explore the condition pages connected to this study.